Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation

NCT02631447 is registered in ClinicalTrials.gov with Fondazione Melanoma Onlus as lead sponsor.

NCT NCT02631447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02631447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
Lead sponsor
Fondazione Melanoma Onlus
Phase
Phase 2
Overall status
Completed
Start date
November 14, 2016
Completion date
May 31, 2024
Enrollment
251 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma